Revolution Medicines acquired up to $2 billion through a flexible funding deal with Royalty Pharma, enhancing their financial runway to internally develop and commercialize RAS(ON) inhibitors worldwide. This approach marks a departure from typical licensing strategies, with a 15-year royalty tied to sales of daraxonrasib, their multi-selective KRAS inhibitor recently granted FDA breakthrough therapy designation. This capital infusion underscores investor confidence in Revolution’s RAS-targeting pipeline and supports expansion beyond U.S. markets.